ReLive’s founders, leadership/management and SAB create a high performing team–built of execution–that bring a wealth of knowledge and experience to the table:

• Over 25 years’ experience of tissue engineering
• Over 200 hospitals using our products
• Over 19,000 patients have been treated
• Produced in Germany for Europe
• Spherox** is the only cell therapy indicated for knee cartilage repair available for adults and pediatric patients

**Authorized in the European Union (EU). Spherox is not approved for sale in the U.S. ReLive’s products may not be available in all geographies. Product availability is subject to the regulatory clearances in individual markets. Please contact us if you have any questions about specific market approvals. For complete product information, including indications, contraindications, warnings, and precautions, please refer to the Instructions for Use / Package insert provided with the product, or contact us for a copy.

ReLive is a pioneering global biotechnology company, founded in 2021 by a team of distinguished visionaries and accomplished experts in the fields of tissue engineering, regenerative medicine, and cell therapy. Backed by venture capital, along with the acquisition of CO.DON, ReLive brings together a diverse team of scientists, surgeons, managers and regulatory experts with extensive and direct experience in biotechnology, to collaborate and develop groundbreaking treatments that improve patient outcomes. Through our ongoing research and development efforts, we strive to make a lasting impact on the field of biotechnology and cell therapy and revolutionize the treatment of orthopedic and reconstructive conditions.